186 related articles for article (PubMed ID: 38567066)
1. Review: Unravelling the Role of DNA Sensing in Alum Adjuvant Activity.
Gatt Z; Gunes U; Raponi A; da Rosa LC; Brewer JM
Discov Immunol; 2023; 2(1):kyac012. PubMed ID: 38567066
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
Richmond P; Hatchuel L; Dong M; Ma B; Hu B; Smolenov I; Li P; Liang P; Han HH; Liang J; Clemens R
Lancet; 2021 Feb; 397(10275):682-694. PubMed ID: 33524311
[TBL] [Abstract][Full Text] [Related]
3. The Immunogenicity of CpG, MF59-like, and Alum Adjuvant Delta Strain Inactivated SARS-CoV-2 Vaccines in Mice.
Xu K; Li J; Lu X; Ge X; Wang K; Wang J; Qiao Z; Quan Y; Li C
Vaccines (Basel); 2024 Jan; 12(1):. PubMed ID: 38250873
[TBL] [Abstract][Full Text] [Related]
4. The immunogenicity of Alum+CpG adjuvant SARS-CoV-2 inactivated vaccine in mice.
Yang J; Li B; Yang D; Wu J; Yang A; Wang W; Lin F; Wan X; Li Y; Chen Z; Lv S; Pang D; Liao W; Meng S; Lu J; Guo J; Wang Z; Shen S
Vaccine; 2023 Sep; 41(41):6064-6071. PubMed ID: 37640568
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil swarming and extracellular trap formation play a significant role in Alum adjuvant activity.
Stephen J; Scales HE; Benson RA; Erben D; Garside P; Brewer JM
NPJ Vaccines; 2017; 2():1. PubMed ID: 29263862
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Immunogenicity of Alum and MF59-Like Adjuvant Inactivated SARS-CoV-2 Vaccines Against SARS-CoV-2 Variants in Elderly Mice.
Bai S; Kang Y; Chen W; Xie H; Zhang L; Lv M; Wang J; Wu J; Zhao W
Viral Immunol; 2023 Oct; 36(8):526-533. PubMed ID: 37625037
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of Adjuvanted Psoralen-Inactivated SARS-CoV-2 Vaccines and SARS-CoV-2 Spike Protein DNA Vaccines in BALB/c Mice.
Sundaram AK; Ewing D; Liang Z; Jani V; Cheng Y; Sun P; Raviprakash K; Wu SJ; Petrovsky N; Defang G; Williams M; Porter KR
Pathogens; 2021 May; 10(5):. PubMed ID: 34069575
[TBL] [Abstract][Full Text] [Related]
8. An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines.
Cao H; Yang S; Wang Y; Luan N; Yin X; Lin K; Liu C
Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835192
[TBL] [Abstract][Full Text] [Related]
9. Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.
Buonsanti C; Balocchi C; Harfouche C; Corrente F; Galli Stampino L; Mancini F; Tontini M; Malyala P; Bufali S; Baudner B; De Gregorio E; Valiante NM; O'Hagan DT; Rappuoli R; D'Oro U
Sci Rep; 2016 Jul; 6():29063. PubMed ID: 27439378
[TBL] [Abstract][Full Text] [Related]
10. Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice.
Grigoryan L; Lee A; Walls AC; Lai L; Franco B; Arunachalam PS; Feng Y; Luo W; Vanderheiden A; Floyd K; Wrenn S; Pettie D; Miranda MC; Kepl E; Ravichandran R; Sydeman C; Brunette N; Murphy M; Fiala B; Carter L; Coffman RL; Novack D; Kleanthous H; O'Hagan DT; van der Most R; McLellan JS; Suthar M; Veesler D; King NP; Pulendran B
NPJ Vaccines; 2022 May; 7(1):55. PubMed ID: 35606518
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.
Burny W; Marchant A; Hervé C; Callegaro A; Caubet M; Fissette L; Gheyle L; Legrand C; Ndour C; Tavares Da Silva F; van der Most R; Willems F; Didierlaurent AM; Yarzabal J;
Vaccine; 2019 Mar; 37(14):2004-2015. PubMed ID: 30850240
[TBL] [Abstract][Full Text] [Related]
12. Different Formulations of Inactivated SARS-CoV-2 Vaccine Candidates in Human Compatible Adjuvants: Potency Studies in Mice Showed Different Platforms of Immune Responses.
Haghighi M; Khorasani A; Karimi P; Keshavarz R; Mahdavi M
Viral Immunol; 2022 Dec; 35(10):663-672. PubMed ID: 36534465
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations.
Nicholson KG; Thompson CI; Klap JM; Wood JM; Batham S; Newman RW; Mischler R; Zambon MC; Stephenson I
Vaccine; 2009 Dec; 28(1):171-8. PubMed ID: 19799843
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of SARS-CoV-2 Trimeric Spike Protein Associated to Poly(I:C) Plus Alum.
Dos-Santos JS; Firmino-Cruz L; da Fonseca-Martins AM; Oliveira-Maciel D; Perez GG; Roncaglia-Pereira VA; Dumard CH; Guedes-da-Silva FH; Santos ACV; Leandro MDS; Ferreira JRM; Guimarães-Pinto K; Conde L; Rodrigues DAS; Silva MVM; Alvim RGF; Lima TM; Marsili FF; Abreu DPB; Ferreira OC; Mohana Borges RDS; Tanuri A; Souza TML; Rossi-Bergmann B; Vale AM; Silva JL; de Oliveira AC; Filardy AD; Gomes AMO; de Matos Guedes HL
Front Immunol; 2022; 13():884760. PubMed ID: 35844561
[TBL] [Abstract][Full Text] [Related]
15. Alum/Toll-Like Receptor 7 Adjuvant Enhances the Expansion of Memory B Cell Compartment Within the Draining Lymph Node.
Vo HTM; Baudner BC; Sammicheli S; Iannacone M; D'Oro U; Piccioli D
Front Immunol; 2018; 9():641. PubMed ID: 29686670
[TBL] [Abstract][Full Text] [Related]
16. A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine.
Tzeng TT; Chai KM; Chen IH; Chang RY; Chiang JR; Liu SJ
Emerg Microbes Infect; 2023 Dec; 12(2):2249130. PubMed ID: 37585273
[TBL] [Abstract][Full Text] [Related]
17. Protection from COVID-19 disease in hamsters vaccinated with subunit SARS-CoV-2 S1 mucosal vaccines adjuvanted with different adjuvants.
Sui Y; Andersen H; Li J; Hoang T; Bekele Y; Kar S; Lewis MG; Berzofsky JA
Front Immunol; 2023; 14():1154496. PubMed ID: 37020550
[TBL] [Abstract][Full Text] [Related]
18. Enhanced immunogenicity, mortality protection, and reduced viral brain invasion by alum adjuvant with an H5N1 split-virion vaccine in the ferret.
Layton RC; Gigliotti A; Armijo P; Myers L; Knight J; Donart N; Pyles J; Vaughan S; Plourde J; Fomukong N; Harrod KS; Gao P; Koster F
PLoS One; 2011; 6(6):e20641. PubMed ID: 21687736
[TBL] [Abstract][Full Text] [Related]
19. Improving the Th1 cellular efficacy of the lead Yersinia pestis rF1-V subunit vaccine using SA-4-1BBL as a novel adjuvant.
Dinc G; Pennington JM; Yolcu ES; Lawrenz MB; Shirwan H
Vaccine; 2014 Sep; 32(39):5035-40. PubMed ID: 25045812
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii.
Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H
BMC Infect Dis; 2017 Jan; 17(1):19. PubMed ID: 28056837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
